3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
109
Leukemia
21
Recurrence
12
Myelodysplastic Syndromes
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Neoplasms
5
Leukemia, Myeloid
5
Hematologic Neoplasms
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Chronic
2
Hematologic Diseases
2
Congenital Abnormalities
2
Thrombocytopenia
1
Sarcoma, Myeloid
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Pathologic Complete Response
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloid Malignancies
1
Meningitis
1
Meningeal Neoplasms
1
Lymphoma, Mantle-Cell
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled